Disease Info Card

Sphingolipidoses

Information about Sphingolipidoses: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Sphingolipidoses

Most recent studies have shown that Sphingolipidoses shares some biological mechanisms with fabry-disease, farber-lipogranulomatosis, gangliosidoses, gangliosidosis-gm1, gaucher-disease, globoid-cell-leukodystrophy, glycogen-storage-disease, inborn-errors-of-metabolism, leukodystrophy, leukodystrophy-metachromatic, lipoidosis, lysosomal-storage-diseases, metabolic-diseases, mucolipidoses, mucopolysaccharidoses, nervousness, niemann-pick-diseases, sandhoff-disease, storage-disease, tay-sachs-disease.

Among the many pathways, these few ones have gauged particular interests from scientists studying Sphingolipidoses, and have been seen in publications frequently: Autophagy, Brain Development, Cell Death, Cell Growth, Cell Proliferation, Cholesterol Esterification, Cholesterol Homeostasis, Endocytosis, Glycosylation, Hyperphosphorylation, Intracellular Transport, Lipid Storage, Lipid Transport, Localization, Myelination, Pathogenesis, Phagocytosis, Regeneration, Senescence, Transport

Quite a number of genes have been found to play important roles in Sphingolipidoses, such as APCS, ARSA, ARSH, ASAH1, CTSA, GALC, GBA, GLB1, HLA-DQA1, MTCH1, NOD2, NPC1, PAEP, PSAP, SH2D1A, SMPD1, SUMF1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.